Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 393Brain Neoplasms 162Glioma 156Gliosarcoma 130Astrocytoma 111Central Nervous System Neoplasms 109Melanoma 75Oligodendroglioma 73Neuroblastoma 44Neoplasms 33Medulloblastoma 33Neoplasm Metastasis 29Recurrence 28Ependymoma 25Sarcoma 23Sarcoma, Ewing 22Rhabdomyosarcoma 18Small Cell Lung Carcinoma 16Lymphoma 16Carcinoma, Non-Small-Cell Lung 16Diffuse Intrinsic Pontine Glioma 15Lung Neoplasms 14Breast Neoplasms 14Ovarian Neoplasms 13Neuroendocrine Tumors 13Choroid Plexus Neoplasms 13Optic Nerve Glioma 11Neuroectodermal Tumors, Primitive 11Spinal Cord Neoplasms 10Rhabdoid Tumor 10

Interventions

Saline Solution 3Ropivacaine 2Propofol 2Morphine 2Mannitol 2Dexmedetomidine 2lonafarnib 1dexketoprofen trometamol 1Temozolomide 1Stem Cell Transplantation 1Remifentanil 1Long-Term Synaptic Depression 1Lidocaine 1HES 130-0.4 1Epinephrine 1Dexamethasone 1Desflurane 1Bupivacaine 1Analgesics, Opioid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Supratentorial Neoplasms × Temozolomide × Clear all
NCT00102648 2024-10-17

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
34 enrolled
CNSSarcoma

Glioblastoma, Supratentorial Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡